688 / 1173
1/03/2016
27
Rationale for combination with anti-PD-L1 Ab
•
Dosing schedule is critical for outcome of combined radio-
immunotherapy –
concurrently is beneficial
53
colorectal cancer
Dovedi et al. Cancer Res 2014
Take home messages
•
Numerous trials in progress combining RT +
targeted agents
•
Challenges
•
Bridge between preclinical and clinical models (tumor
growth delay vs tumor control (TCD
50
))
•
Translational research
•
Biomarkers
•
Trial design – patient stratification
•
New toxicities – late effects